Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

0 seconds of 0 secondsVolume 90%

00:00

Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

2021 ASTRO Annual Meeting

Daniel J. Ma, MD, of the Mayo Clinic Alix School of Medicine, discusses results from a phase III study of patients with HPV-associated oropharyngeal squamous cell carcinoma. Comparing a 2-week course of de-escalated adjuvant radiation therapy with the standard 6-week course, investigators found that the shorter treatment appeared to have less toxicity, higher quality of life, and similar disease control as the longer standard-of-care treatment (Abstract LBA1).

Shauna Campbell, DO, on Head and Neck Cancer: Toxicity Associated With Hypofractionated IMRT

Shauna Campbell, DO, of Cleveland Clinic, discusses results from her study that showed hypofractionated intensity-modulated radiation therapy (H-IMRT) in the definitive or postoperative treatment of head and neck cancers using ≥ 50 Gy in 20 fractions appears to be safe and well tolerated with modest toxicity. Dr. Campbell suggests that prospective studies comparing the safety and efficacy of H-IMRT with those of conventionally fractionated IMRT are warranted (Abstract 2313).

Breast Cancer

Lung Cancer

The ASCO Post Staff

C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers

C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the first randomized trial of stereotactic body radiation therapy (SBRT) to treat oligoprogressive, metastatic lung and breast cancers. The standard of care for patients with these types of tumors is to switch to a different systemic treatment. Adding local therapy such as SBRT may help treat drug-resistant lesions (Abstract LBA3).

Solid Tumors

The ASCO Post Staff

Robert A. Olson, MD, on Oligometastases: New Data on Stereotactic Ablative Radiotherapy

Robert A. Olson, MD, of the University of British Columbia, discusses phase II findings from the SABR-5 trial on stereotactic ablative radiotherapy for up to five oligometastases. Although toxicity of liver and adrenal metastases warrants caution, the trial seemed to show that this type of radiation treatment is relatively safe and should be studied further, given the long overall survival in this patient population (Abstract 6).

Breast Cancer

The ASCO Post Staff

Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial

Yongbae Kim, MD, of the Yonsei Cancer Center and Yonsei University College of Medicine, discusses findings that showed the use of internal mammary area irradiation (IMNI) in regional nodal irradiation did not significantly improve disease-free survival for women with node-positive breast cancer. However, patients with medially or centrally located tumors may be considered for treatment with IMNI (Abstract 2).

Issues in Oncology

The ASCO Post Staff

Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for widespread disease might improve survival and lead to a cure.

Apr

Today In Oncology

Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

Related Videos

Shauna Campbell, DO, on Head and Neck Cancer: Toxicity Associated With Hypofractionated IMRT

C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers

Robert A. Olson, MD, on Oligometastases: New Data on Stereotactic Ablative Radiotherapy

Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial

Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Comparing Biopsy Techniques for Prostate Cancer Detection

Characteristics of Nasopharyngeal Carcinoma in the United States

Grocery Store Choice Could Impact Obesity Related Cancer Mortality